Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
89.6M
-
Number of holders
-
172
-
Total 13F shares, excl. options
-
72.9M
-
Shares change
-
-8.41M
-
Total reported value, excl. options
-
$819M
-
Value change
-
+$44.4M
-
Put/Call ratio
-
6.51
-
Number of buys
-
91
-
Number of sells
-
-125
-
Price
-
$11.23
Significant Holders of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) as of Q2 2025
244 filings reported holding VERV - Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2025.
Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) has 172 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 72.9M shares
of 89.6M outstanding shares and own 81.41% of the company stock.
Largest 10 shareholders include Alphabet Inc. (12.2M shares), BlackRock, Inc. (7.36M shares), Pentwater Capital Management LP (6.72M shares), VANGUARD GROUP INC (4.19M shares), Casdin Capital, LLC (4.1M shares), FARALLON CAPITAL MANAGEMENT LLC (3.61M shares), ALPINE ASSOCIATES MANAGEMENT INC. (2.74M shares), STATE STREET CORP (2.63M shares), ARCH Venture Management, LLC (2.01M shares), and UBS Group AG (1.87M shares).
This table shows the top 172 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.